Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,574 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05948813RecruitingPhase 2
TY-9591 for EGFR-mutant lung cancer spread to the brain
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Daphne, AlabamaAges 18 years+ - NCT05614739RecruitingPhase 1
Study of vepugratinib for cancers with FGFR3 gene changes
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Tucson, ArizonaAges 18 years+ - NCT07456046RecruitingPhase 1
Study of D3S-003 for advanced solid tumors with KRAS G12D mutation
This trial tests a new medicine called D3S-003 in people whose cancer has a specific change (mutation) known as KRAS G12D. The medicine aims to target and attack cancer cells with this mutation. It may be an option if standard treatments have stopped working or are not available.
New Haven, ConnecticutAges 18 years+ - NCT07546812RecruitingPhase 2
Testing Denikitug for advanced stomach and esophageal cancer
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Boston, MassachusettsAges 18 years+ - NCT07429110Recruiting
ColoSeal device study for rectal cancer surgery patients
This study tests a device called ColoSeal that protects the connection made during rectal cancer surgery. It is for patients who are having surgery to remove the tumor and reattach the bowel, and who also need a temporary ostomy.
Orlando, FloridaAges 22–75 - NCT07631793RecruitingPhase 1
YKYY031 injection for advanced solid tumors with specific genetic mutations
This early-stage trial tests a new cancer treatment (YKYY031) given by injection for advanced colorectal or pancreatic cancer that has stopped responding to standard treatments. The drug is designed to target specific genetic changes (mutations) found in some tumors, and your immune system must match a particular genetic marker (HLA-A*11:01) for the drug to work.
Beijing, Beijing MunicipalityAges 18–75 - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Baltimore, MarylandAges 18 years+ - NCT07128303RecruitingPhase 1
Study of a new drug for advanced solid tumors with a specific genetic feature
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07221851RecruitingPhase 3
Weekly vs daily growth hormone for short stature in children
This trial tests a weekly growth hormone injection (lonapegsomatropin) compared to the standard daily growth hormone shot in children with short stature due to certain conditions. It aims to see if the weekly shot works as well or better and is safe.
Palo Alto, CaliforniaAges 2–17 - NCT06569147RecruitingPhase 1/Phase 2
Elranatamab for AL amyloidosis that has returned or not responded
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
New Haven, ConnecticutAges 18 years+ - NCT06059495RecruitingPhase 2
Watch and wait with dostarlimab for localized stomach cancer
This trial tests a drug called dostarlimab for people with a specific type of stomach cancer that has not spread. The goal is to see if the drug can make the tumor disappear, so you might not need surgery right away.
BesançonAges 18–75 - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07231211RecruitingPhase 1/Phase 2
Testing SHR-4610 for advanced solid tumors
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
Hangzhou, ZhejiangAges 18–75 - NCT07113743Enrolling by invitationPhase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
Bethesda, MarylandAges 3–60 - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT05923684Recruiting
English prostate cancer visit feedback tool for shared decisions
This trial tests an English computer tool that gives feedback during prostate cancer treatment visits. It aims to help you and your clinician make more informed, shared decisions about next treatment steps.
Los Angeles, CaliforniaAges 18 years+ - NCT06526819RecruitingPhase 1/Phase 2
New drug SMP-3124LP for advanced solid tumors
This trial tests a new drug called SMP-3124LP for people with advanced solid tumors that no longer respond to standard treatments. It is given in two phases: first to find the best dose (dose escalation) and then to see how well it works in specific cancer types (dose expansion).
Los Angeles, CaliforniaAges 18 years+ - NCT07533708RecruitingPhase 1
Testing HLX3902 for advanced cancers, especially prostate cancer
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
NanchangAges 18 years+ - NCT07750067RecruitingPhase 2
Combination therapy for advanced melanoma with NRAS mutation
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18 years+ - NCT05389293RecruitingPhase 2
Mosunetuzumab with or without zanubrutinib for follicular lymphoma
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT07089953Recruiting
Does the doctor's computer use affect your visit?
This study looks at whether a small change in how doctors use electronic health records can improve how compassionate and professional they seem during your clinic visit. If you join, you would fill out a short survey after your appointment.
Houston, TexasAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Duarte, CaliforniaAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,574 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.